Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch

Sage Therapeutics was mostly focused on reviewing safety for its Alzheimer’s disease drug, but early data shows the therapy may also improve executive performance, learning and memory in patients with mild cognitive impairment and dementia—but there's a catch.